-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the 100 billion market value of "Chinese medicine stock king" Katazai Zhen announced the results of the first half of 2022, with operating income of 4.
423 billion yuan and net profit of 1.
314 billion yuan, which are the best results
since the listing.
The capital market has always placed high hopes on Katazai, the company has a first-class protected variety of traditional Chinese medicine and a number of exclusive proprietary Chinese medicines, the main battlefield in the retail terminal by the impact of collection and procurement is limited, the prospect is good
.
However, the price increase of raw materials inevitably affects the company's profits, and the company is actively laying out 1 new drugs to accelerate innovation and transformation
.
423 billion yuan and net profit of 1.
314 billion yuan, which are the best results
since the listing.
The capital market has always placed high hopes on Katazai, the company has a first-class protected variety of traditional Chinese medicine and a number of exclusive proprietary Chinese medicines, the main battlefield in the retail terminal by the impact of collection and procurement is limited, the prospect is good
.
However, the price increase of raw materials inevitably affects the company's profits, and the company is actively laying out 1 new drugs to accelerate innovation and transformation
.
Core products in full volume! The online pharmacy of Katazai is selling well, and Angong Niuhuang Pills have become a new hit
It was listed on the Shanghai Stock Exchange in 2003 and became one of the first batch of "Chinese time-honored brand" enterprises identified by the Ministry of Commerce of the People's Republic of China
in 2006.
The company mainly focuses on the liver disease drug market dominated by the tablets, and the revenue of the company's business segment in the first half of 2022 reached a new high, approaching 2 billion yuan for the first time; In July 2020, the company successfully acquired 51% of the equity of Longhui Pharmaceutical, and collected a number of traditional classic Chinese proprietary Chinese medicines such as Angong Niuhuang Pill (double natural product specifications), and after hard work, the revenue of the cardiovascular and cerebrovascular drug sector based on Angong Niuhuang Pill in the first half of 2022 exceeded 100 million yuan
for the first time.
"Do excellent tablets, do Daangong beef yellow pills, and strengthen cosmetics" has become a new development strategy
for tablets.
in 2006.
The company mainly focuses on the liver disease drug market dominated by the tablets, and the revenue of the company's business segment in the first half of 2022 reached a new high, approaching 2 billion yuan for the first time; In July 2020, the company successfully acquired 51% of the equity of Longhui Pharmaceutical, and collected a number of traditional classic Chinese proprietary Chinese medicines such as Angong Niuhuang Pill (double natural product specifications), and after hard work, the revenue of the cardiovascular and cerebrovascular drug sector based on Angong Niuhuang Pill in the first half of 2022 exceeded 100 million yuan
for the first time.
"Do excellent tablets, do Daangong beef yellow pills, and strengthen cosmetics" has become a new development strategy
for tablets.
Figure 1: Revenue of the liver disease drug sector in the past three years (unit: 100 million yuan)
Source: the company's semi-annual report, annual report
The company's liver disease drug fist products involve tablets (lozenges) and tablets capsules, and the sales channels focus on mainstream chains
.
According to data from the intranet, in 2021, in the terminal liver disease drug market of physical pharmacies in China's cities, the sales of tablets (lozenges) were 990 million yuan; last year, after experiencing the storm of crazy seizures of lozenges, the sales of "homogeneous and identical" tablets and capsules ushered in a wave of soaring, breaking through 100 million yuan for the first time, with a growth rate of 47%.
.
According to data from the intranet, in 2021, in the terminal liver disease drug market of physical pharmacies in China's cities, the sales of tablets (lozenges) were 990 million yuan; last year, after experiencing the storm of crazy seizures of lozenges, the sales of "homogeneous and identical" tablets and capsules ushered in a wave of soaring, breaking through 100 million yuan for the first time, with a growth rate of 47%.
In order to crack down on scalpers and grasp the channel initiative, Katazai opened up online channels
such as the Tmall flagship store of Katazai Pharmacy and the Jingdong flagship store of Katazai Pharmacy in May and July 2021 respectively.
According to the Database of China Online Pharmacies on The Inner Network, in 2021, the katazai (lozenge) broke through the sales threshold of 900 million yuan with a growth rate of 1282%, and the tablets capsules won a sales performance of 100 million yuan with a growth rate of 327%, both of which achieved a rapid increase, and also consolidated the leading position
in the use of liver disease.
such as the Tmall flagship store of Katazai Pharmacy and the Jingdong flagship store of Katazai Pharmacy in May and July 2021 respectively.
According to the Database of China Online Pharmacies on The Inner Network, in 2021, the katazai (lozenge) broke through the sales threshold of 900 million yuan with a growth rate of 1282%, and the tablets capsules won a sales performance of 100 million yuan with a growth rate of 327%, both of which achieved a rapid increase, and also consolidated the leading position
in the use of liver disease.
From the perspective of the gross profit margin of the company's main products, since the first half of 2020, the gross profit margin of the liver disease drug sector has basically remained above
80%.
80%.
Figure 2: Revenue of cardiovascular and cerebrovascular drugs in the past three years (unit: 10,000 yuan)
Source: the company's semi-annual report, annual report
With the increase in market demand, Angong Niuhuang Pill has grown into more than 4 billion varieties in retail terminals (China's urban physical pharmacies + online pharmacies), and its sales growth rate in the past two years has been 21% and 37%, respectively, maintaining a rapid upward momentum
.
.
Katazai brand Angong Beef Yellow Pills selected natural musk, natural ox yolk and other authentic medicinal materials, following the ancient method of concoction and gold leaf coating and other traditional processes, has been successfully introduced to the market, with the help of the original brand advantages and channel advantages of Katazai, fully covering nearly 400 experience halls and more than 50 chains of 5,000 terminal stores across the country, the product has become the company's potential new products
.
Driven by the katazai brand Angong Niuhuang Pill, the revenue of the company's cardiovascular and cerebrovascular drug sector exceeded 100 million yuan in the first half of 2022, and the gross profit margin was 47.
63%.
.
Driven by the katazai brand Angong Niuhuang Pill, the revenue of the company's cardiovascular and cerebrovascular drug sector exceeded 100 million yuan in the first half of 2022, and the gross profit margin was 47.
63%.
Natural musk and natural bovine yolk are the main ingredients of the katazai series of products and Angong beef yolk pills, and the shortage of resources and rising prices have caused great challenges to the supply of raw materials for the company, and from time to time have triggered speculation in the market about price increases
.
Recently, some media asked the company whether there is a possibility of price increases in related products, and learned from the company that "there is no relevant plan at present, depending on whether the cost will rise.
"
.
Recently, some media asked the company whether there is a possibility of price increases in related products, and learned from the company that "there is no relevant plan at present, depending on whether the cost will rise.
"
In addition to physical pharmacies and online pharmacies, the company's sales channels also include Katazai experience halls and regional distribution
.
The sales model of "Katazai Experience Hall" was launched in 2015, through the establishment of the experience hall, it has improved the awareness and loyalty of social consumer groups to the Katazai brand, and also improved the desire to buy products, with nearly 400 experience halls
in the country.
In the 2022 semi-annual report, Katazai mentioned that it is necessary to build a "Katazai Famous Medical Center", which will introduce famous Chinese medicines from inside and outside the province to create a collection platform for famous Chinese medicines, a highland for traditional Chinese medicine health services and an industrial agglomeration area to meet the diversified and multi-level health service needs
of the people.
In recent years, many long-established Chinese medicine halls have adopted the "famous doctor + famous drug" model to operate, with remarkable results, the limelight is no different, how effective the company's measures are, we will continue to pay attention
to.
.
The sales model of "Katazai Experience Hall" was launched in 2015, through the establishment of the experience hall, it has improved the awareness and loyalty of social consumer groups to the Katazai brand, and also improved the desire to buy products, with nearly 400 experience halls
in the country.
In the 2022 semi-annual report, Katazai mentioned that it is necessary to build a "Katazai Famous Medical Center", which will introduce famous Chinese medicines from inside and outside the province to create a collection platform for famous Chinese medicines, a highland for traditional Chinese medicine health services and an industrial agglomeration area to meet the diversified and multi-level health service needs
of the people.
In recent years, many long-established Chinese medicine halls have adopted the "famous doctor + famous drug" model to operate, with remarkable results, the limelight is no different, how effective the company's measures are, we will continue to pay attention
to.
With 14 exclusive proprietary Chinese medicines in hand, 5 major products lead the market! 6 new Class 1 drugs are poised
Starting with proprietary Chinese medicine, the company has a first-class protected variety of traditional Chinese medicine and a number of exclusive proprietary Chinese medicines, and in recent years, the company has actively promoted industrial diversification and product diversification transformation
by using a variety of means.
by using a variety of means.
In 2020, the company successfully acquired 51% of the equity of Longhui Pharmaceutical, and successfully collected hundreds of drug approvals
.
At present, Katazai has 73 proprietary Chinese medicine products (92 approvals), distributed in 24 sub-categories, thanks to the acquisition of Longhui Pharmaceutical, the number of chemical drug products of the company has increased to 66 (the number of approvals is 66), distributed in 26 sub-categories
.
.
At present, Katazai has 73 proprietary Chinese medicine products (92 approvals), distributed in 24 sub-categories, thanks to the acquisition of Longhui Pharmaceutical, the number of chemical drug products of the company has increased to 66 (the number of approvals is 66), distributed in 26 sub-categories
.
Table 1: Exclusive proprietary Chinese medicine under Tablets
Source: Minnet MID Drug Index Comprehensive Database
Longhui Pharmaceutical's exclusive product, Ginseng Turtle Kidney Supplement Oral Liquid, has the effect of tonifying the kidney and spleen, generating lean pulp, and has a certain improvement effect on children with mental retardation, and in 2021, the terminal pediatric other drug market in China's online pharmacies is TOP12 products
.
Earlier in the pediatric chinese medicine market, there were only two major products of pediatric cough syrup and refined monkey jujube powder, and the addition of ginseng turtle kidney oral liquid is expected to enhance the company's competitive advantage
in the pediatric chinese medicine market.
.
Earlier in the pediatric chinese medicine market, there were only two major products of pediatric cough syrup and refined monkey jujube powder, and the addition of ginseng turtle kidney oral liquid is expected to enhance the company's competitive advantage
in the pediatric chinese medicine market.
Tablets (lozenges), tablets capsules, inchoping liver capsules are the best-selling liver disease drugs, in 2021 in China's urban physical pharmacies terminal liver disease drug market, the three major products ranked top 1, TOP3, TOP10
.
In the past two years, tablets (lozenges) and tablets capsules have become extremely popular in online pharmacies and have become TOP1 and TOP2 products
.
The absolute leading position of Katazai in the retail market for liver disease drugs cannot be shaken
.
.
In the past two years, tablets (lozenges) and tablets capsules have become extremely popular in online pharmacies and have become TOP1 and TOP2 products
.
The absolute leading position of Katazai in the retail market for liver disease drugs cannot be shaken
.
Compound tablets of Zi Zi Ointment has the effect of clearing heat, detoxification, analgesicity, for shingles, herpes simplex, impetigo, folliculitis, acne, carbuncle furuncles
.
In 2021, the product ranked top 2 products in the chinese urban physical pharmacy terminal dermatology and other drug markets, and ranked top 15
in China's online pharmacy terminals.
.
In 2021, the product ranked top 2 products in the chinese urban physical pharmacy terminal dermatology and other drug markets, and ranked top 15
in China's online pharmacy terminals.
14 exclusive products have laid a large number of rivers and mountains for Katazai, but in recent years, the impact of national policies and the risk of rising raw material prices should not be underestimated, and transformation is imperative
.
Katazai has continuously increased investment in research and development, focused on the secondary development of independent advantageous varieties, and guided by clinical value, laid out new drug research and development pipelines such as innovative drugs of traditional Chinese medicine, classic recipes, and innovative drugs of chemical drugs, and continuously enriched the reserve of new products to boost
the company's performance.
According to the semi-annual report data, the company's R & D investment in the first half of 2022 increased by 82.
18%.
.
Katazai has continuously increased investment in research and development, focused on the secondary development of independent advantageous varieties, and guided by clinical value, laid out new drug research and development pipelines such as innovative drugs of traditional Chinese medicine, classic recipes, and innovative drugs of chemical drugs, and continuously enriched the reserve of new products to boost
the company's performance.
According to the semi-annual report data, the company's R & D investment in the first half of 2022 increased by 82.
18%.
Figure 3: Tablets are undergoing clinical products
Source: Minnet China Drug Clinical Trial Publicity Library
Tablets have become a veritable variety of traditional Chinese medicine, in 2020 the new lozenges for the treatment of non-resectable primary liver cancer indications were approved clinically, is currently in the phase II clinical stage, the data show that the first case of subjects has been enrolled in January this year
.
In 2021, the three major terminal 6 major markets (the statistical scope is detailed at the end of this article) The market size of the chinese patent medicine oncology disease is more than 20 billion yuan, the retail market (urban physical pharmacies + online pharmacies) maintains a positive growth trend, if the new indications are successfully approved, with the company's channel layout and brand effect in the retail market, Katazai is expected to meet another wave of volume
.
.
In 2021, the three major terminal 6 major markets (the statistical scope is detailed at the end of this article) The market size of the chinese patent medicine oncology disease is more than 20 billion yuan, the retail market (urban physical pharmacies + online pharmacies) maintains a positive growth trend, if the new indications are successfully approved, with the company's channel layout and brand effect in the retail market, Katazai is expected to meet another wave of volume
.
Chinese medicine 5 new drugs strychnine total alkali vesicle gel is intended to be used for knee osteoarthritis cold resistance choroid evidence caused by pain swelling and other symptoms, tablets and Yingkerui reached a consultation in 2016, the company provided research costs of 12 million yuan, agreed that both parties to jointly carry out clinical research of the new drug, approved clinical in 2018, is currently in the phase I clinical stage
.
.
The company's new Chinese medicine class 1 drugs also include PZH1201 for the treatment of irritable bowel syndrome, PZH1203 for the treatment of osteoarthritis, and PZH1204
for the treatment of generalized anxiety disorder.
for the treatment of generalized anxiety disorder.
In terms of new drugs of chemical drugs Class 1, PZH2111 tablets for the treatment of advanced solid tumors/hepatic cholangiobladic cell tumors were approved for clinical trials in 2020 and are currently undergoing Phase I/II clinical trials, and the data show that the first subject has been enrolled
in January this year.
Anti-tumor class 1 new drugs are currently a hot area for domestic pharmaceutical companies to develop, and the product is expected to become the first new chemical drug class 1 drug listed in Tablets
.
in January this year.
Anti-tumor class 1 new drugs are currently a hot area for domestic pharmaceutical companies to develop, and the product is expected to become the first new chemical drug class 1 drug listed in Tablets
.
In 2020, the company also won the clinical approval of PZH2108 tablets for cancerous pain; In 2021, the clinical approval of PZH2107 (LDS tablets, collaborative project) for the treatment of fibromyalgia will be obtained
.
The company is progressing smoothly in the research and development of new products, and the road of transformation of Katazai is becoming more and more stable
.
.
The company is progressing smoothly in the research and development of new products, and the road of transformation of Katazai is becoming more and more stable
.
There is only 1 Chinese medicine stock with a market value of 100 billion! Focus on retail, strengthen innovation.
.
.
Chinese medicine is still promising
.
.
Chinese medicine is still promising
As of the noon close on August 25, the threshold of the market value of the TOP10 A-share Chinese medicine enterprises was more than 20 billion yuan, but only one of them could stick to the market value of 100 billion yuan, and the old rival Yunnan Baiyao fell to 95.
55 billion yuan, and the gap between the two was getting bigger and bigger
.
At present, 6 of the TOP10 companies have announced the results of the first half of this year, and Katazai, Baiyunshan, China Resources Sanjiu, Dong'e Ejiao, and Jichuan Pharmaceutical have achieved a double harvest
of revenue and net profit.
55 billion yuan, and the gap between the two was getting bigger and bigger
.
At present, 6 of the TOP10 companies have announced the results of the first half of this year, and Katazai, Baiyunshan, China Resources Sanjiu, Dong'e Ejiao, and Jichuan Pharmaceutical have achieved a double harvest
of revenue and net profit.
Table 2: A stock market value TOP10 Chinese medicine enterprises
Note: Statistics as of 12:00 on August 24
The increase in revenue of Katazai is mainly due to the strengthening of market planning and expansion of sales channels, and the increase in sales revenue of the Company and its holding subsidiary Xiamen Katazai Hongren Pharmaceutical (consolidated); The increase in net profit was mainly due to increased
sales of the core product, the Katazai series.
The company's new strategic achievements of "multi-core drive, two-way development" are obvious, coupled with increased investment in innovation, which is expected to create a new growth point for the
company.
sales of the core product, the Katazai series.
The company's new strategic achievements of "multi-core drive, two-way development" are obvious, coupled with increased investment in innovation, which is expected to create a new growth point for the
company.
Baiyun Mountain's large commercial sector accounted for more than 60%, and the revenue in the first half of the year rose slightly, with a gross profit margin of 6.
97%, while the proportion of The Great Southern Medicine and the Great Health Sector was in the range of 10%-20%, and the gross profit margin reached more than
45%.
Affected by the epidemic, collection, medical insurance catalog adjustment and other factors, the company's performance is under pressure, but there is still some growth, the second half of the year will continue to do fine and large southern medicine, stronger and better health, deeper and more live business, bigger and more refined medical treatment, and increase investment and cohesion innovation
.
97%, while the proportion of The Great Southern Medicine and the Great Health Sector was in the range of 10%-20%, and the gross profit margin reached more than
45%.
Affected by the epidemic, collection, medical insurance catalog adjustment and other factors, the company's performance is under pressure, but there is still some growth, the second half of the year will continue to do fine and large southern medicine, stronger and better health, deeper and more live business, bigger and more refined medical treatment, and increase investment and cohesion innovation
.
In recent years, CR 39 has continuously adjusted the proportion of business segments, and the proportion of CHC's health consumer goods business increased to 65.
89% in the first half of 2022, while the proportion of prescription drugs fell to 29.
73%.
The company said that the overall operating performance in the first half of the year was mainly driven by the growth of CHC business, especially the rapid growth of professional brands, big health and other businesses; However, the growth rate of the formula granule business affected by the national standard switching and the provincial standard promotion speed has declined, the sales of the Traditional Chinese medicine injection business affected by the epidemic and the collection policy have declined year-on-year, and the growth rate of the prescription drug business has been affected
.
89% in the first half of 2022, while the proportion of prescription drugs fell to 29.
73%.
The company said that the overall operating performance in the first half of the year was mainly driven by the growth of CHC business, especially the rapid growth of professional brands, big health and other businesses; However, the growth rate of the formula granule business affected by the national standard switching and the provincial standard promotion speed has declined, the sales of the Traditional Chinese medicine injection business affected by the epidemic and the collection policy have declined year-on-year, and the growth rate of the prescription drug business has been affected
.
The net profit of Dong'e Ejiao in the first half of 2022 increased by 106%, the painful period of "destocking" has passed, and the performance recovery period has arrived
.
The proportion of ejiao and series products rose to 87.
30%, the proportion of other drugs and health care products increased to 7.
55%, the gross profit margin of the two major business segments remained above 60%, and the company is gradually reducing the proportion
of donkey breeding and sales with lower gross profit margin.
.
The proportion of ejiao and series products rose to 87.
30%, the proportion of other drugs and health care products increased to 7.
55%, the gross profit margin of the two major business segments remained above 60%, and the company is gradually reducing the proportion
of donkey breeding and sales with lower gross profit margin.
Jichuan Pharmaceutical's pediatric exclusive products, pediatric fever clearing granules and second-line protein iron succinate oral solution, gastric digestion oral liquid and Huanglong cough granules, contributed major increments
.
In addition to existing products, the company continues to increase the research and development and introduction of new products, actively carry out the secondary development of existing key varieties, and continuously enrich reserve products
.
.
In addition to existing products, the company continues to increase the research and development and introduction of new products, actively carry out the secondary development of existing key varieties, and continuously enrich reserve products
.
Judging from the performance of various enterprises in the first half of the year, the retail market (the growth rate of online pharmacies is amazing), and the focus on patient consumption have achieved good results, and the partial consumption of traditional Chinese medicine can become a policy haven
.
The main theme of innovation remains unchanged, independent research and development, cooperative research and development, the introduction of products and other multi-mode joint promotion, enterprises according to their own situation to choose is still promising
.
At present, the capital market is very concerned about Chinese medicine innovation, brand Chinese medicine, exclusive products, Chinese medicine formula granules, new crown prevention and treatment related Chinese medicine targets, and these areas can also become new growth points for
the company's performance.
.
The main theme of innovation remains unchanged, independent research and development, cooperative research and development, the introduction of products and other multi-mode joint promotion, enterprises according to their own situation to choose is still promising
.
At present, the capital market is very concerned about Chinese medicine innovation, brand Chinese medicine, exclusive products, Chinese medicine formula granules, new crown prevention and treatment related Chinese medicine targets, and these areas can also become new growth points for
the company's performance.
Data source: the company's semi-annual report, intranet database note: intranet "China's three major terminals and 6 major market competition pattern", the statistical scope is: urban public hospitals and county-level public hospitals, urban community centers and township health centers, urban physical pharmacies and online pharmacies, excluding private hospitals, private clinics, village clinics, excluding county and rural pharmacies; The above sales are calculated
based on the average retail price of the product at the terminal.
Statistics as of August 25, if there are any errors or omissions, welcome to correct
.
based on the average retail price of the product at the terminal.
Statistics as of August 25, if there are any errors or omissions, welcome to correct
.
Recently, the 100 billion market value of "Chinese medicine stock king" Katazai Zhen announced the results of the first half of 2022, with operating income of 4.
423 billion yuan and net profit of 1.
314 billion yuan, which are the best results
since the listing.
The capital market has always placed high hopes on Katazai, the company has a first-class protected variety of traditional Chinese medicine and a number of exclusive proprietary Chinese medicines, the main battlefield in the retail terminal by the impact of collection and procurement is limited, the prospect is good
.
However, the price increase of raw materials inevitably affects the company's profits, and the company is actively laying out 1 new drugs to accelerate innovation and transformation
.
423 billion yuan and net profit of 1.
314 billion yuan, which are the best results
since the listing.
The capital market has always placed high hopes on Katazai, the company has a first-class protected variety of traditional Chinese medicine and a number of exclusive proprietary Chinese medicines, the main battlefield in the retail terminal by the impact of collection and procurement is limited, the prospect is good
.
However, the price increase of raw materials inevitably affects the company's profits, and the company is actively laying out 1 new drugs to accelerate innovation and transformation
.
Core products in full volume! The online pharmacy of Katazai is selling well, and Angong Niuhuang Pills have become a new hit
Core products in full volume! The online pharmacy of Katazai is selling well, and Angong Niuhuang Pills have become a new hit It was listed on the Shanghai Stock Exchange in 2003 and became one of the first batch of "Chinese time-honored brand" enterprises identified by the Ministry of Commerce of the People's Republic of China
in 2006.
The company mainly focuses on the liver disease drug market dominated by the tablets, and the revenue of the company's business segment in the first half of 2022 reached a new high, approaching 2 billion yuan for the first time; In July 2020, the company successfully acquired 51% of the equity of Longhui Pharmaceutical, and collected a number of traditional classic Chinese proprietary Chinese medicines such as Angong Niuhuang Pill (double natural product specifications), and after hard work, the revenue of the cardiovascular and cerebrovascular drug sector based on Angong Niuhuang Pill in the first half of 2022 exceeded 100 million yuan
for the first time.
"Do excellent tablets, do Daangong beef yellow pills, and strengthen cosmetics" has become a new development strategy
for tablets.
Cosmetics Cosmeticsin 2006.
The company mainly focuses on the liver disease drug market dominated by the tablets, and the revenue of the company's business segment in the first half of 2022 reached a new high, approaching 2 billion yuan for the first time; In July 2020, the company successfully acquired 51% of the equity of Longhui Pharmaceutical, and collected a number of traditional classic Chinese proprietary Chinese medicines such as Angong Niuhuang Pill (double natural product specifications), and after hard work, the revenue of the cardiovascular and cerebrovascular drug sector based on Angong Niuhuang Pill in the first half of 2022 exceeded 100 million yuan
for the first time.
"Do excellent tablets, do Daangong beef yellow pills, and strengthen cosmetics" has become a new development strategy
for tablets.
Figure 1: Revenue of the liver disease drug sector in the past three years (unit: 100 million yuan)
Source: the company's semi-annual report, annual report
The company's liver disease drug fist products involve tablets (lozenges) and tablets capsules, and the sales channels focus on mainstream chains
.
According to data from the intranet, in 2021, in the terminal liver disease drug market of physical pharmacies in China's cities, the sales of tablets (lozenges) were 990 million yuan; last year, after experiencing the storm of crazy seizures of lozenges, the sales of "homogeneous and identical" tablets and capsules ushered in a wave of soaring, breaking through 100 million yuan for the first time, with a growth rate of 47%.
.
According to data from the intranet, in 2021, in the terminal liver disease drug market of physical pharmacies in China's cities, the sales of tablets (lozenges) were 990 million yuan; last year, after experiencing the storm of crazy seizures of lozenges, the sales of "homogeneous and identical" tablets and capsules ushered in a wave of soaring, breaking through 100 million yuan for the first time, with a growth rate of 47%.
In order to crack down on scalpers and grasp the channel initiative, Katazai opened up online channels
such as the Tmall flagship store of Katazai Pharmacy and the Jingdong flagship store of Katazai Pharmacy in May and July 2021 respectively.
According to the Database of China Online Pharmacies on The Inner Network, in 2021, the katazai (lozenge) broke through the sales threshold of 900 million yuan with a growth rate of 1282%, and the tablets capsules won a sales performance of 100 million yuan with a growth rate of 327%, both of which achieved a rapid increase, and also consolidated the leading position
in the use of liver disease.
such as the Tmall flagship store of Katazai Pharmacy and the Jingdong flagship store of Katazai Pharmacy in May and July 2021 respectively.
According to the Database of China Online Pharmacies on The Inner Network, in 2021, the katazai (lozenge) broke through the sales threshold of 900 million yuan with a growth rate of 1282%, and the tablets capsules won a sales performance of 100 million yuan with a growth rate of 327%, both of which achieved a rapid increase, and also consolidated the leading position
in the use of liver disease.
From the perspective of the gross profit margin of the company's main products, since the first half of 2020, the gross profit margin of the liver disease drug sector has basically remained above
80%.
80%.
Figure 2: Revenue of cardiovascular and cerebrovascular drugs in the past three years (unit: 10,000 yuan)
Source: the company's semi-annual report, annual report
With the increase in market demand, Angong Niuhuang Pill has grown into more than 4 billion varieties in retail terminals (China's urban physical pharmacies + online pharmacies), and its sales growth rate in the past two years has been 21% and 37%, respectively, maintaining a rapid upward momentum
.
.
Katazai brand Angong Beef Yellow Pills selected natural musk, natural ox yolk and other authentic medicinal materials, following the ancient method of concoction and gold leaf coating and other traditional processes, has been successfully introduced to the market, with the help of the original brand advantages and channel advantages of Katazai, fully covering nearly 400 experience halls and more than 50 chains of 5,000 terminal stores across the country, the product has become the company's potential new products
.
Driven by the katazai brand Angong Niuhuang Pill, the revenue of the company's cardiovascular and cerebrovascular drug sector exceeded 100 million yuan in the first half of 2022, and the gross profit margin was 47.
63%.
.
Driven by the katazai brand Angong Niuhuang Pill, the revenue of the company's cardiovascular and cerebrovascular drug sector exceeded 100 million yuan in the first half of 2022, and the gross profit margin was 47.
63%.
Natural musk and natural bovine yolk are the main ingredients of the katazai series of products and Angong beef yolk pills, and the shortage of resources and rising prices have caused great challenges to the supply of raw materials for the company, and from time to time have triggered speculation in the market about price increases
.
Recently, some media asked the company whether there is a possibility of price increases in related products, and learned from the company that "there is no relevant plan at present, depending on whether the cost will rise.
"
.
Recently, some media asked the company whether there is a possibility of price increases in related products, and learned from the company that "there is no relevant plan at present, depending on whether the cost will rise.
"
In addition to physical pharmacies and online pharmacies, the company's sales channels also include Katazai experience halls and regional distribution
.
The sales model of "Katazai Experience Hall" was launched in 2015, through the establishment of the experience hall, it has improved the awareness and loyalty of social consumer groups to the Katazai brand, and also improved the desire to buy products, with nearly 400 experience halls
in the country.
In the 2022 semi-annual report, Katazai mentioned that it is necessary to build a "Katazai Famous Medical Center", which will introduce famous Chinese medicines from inside and outside the province to create a collection platform for famous Chinese medicines, a highland for traditional Chinese medicine health services and an industrial agglomeration area to meet the diversified and multi-level health service needs
of the people.
In recent years, many long-established Chinese medicine halls have adopted the "famous doctor + famous drug" model to operate, with remarkable results, the limelight is no different, how effective the company's measures are, we will continue to pay attention
to.
.
The sales model of "Katazai Experience Hall" was launched in 2015, through the establishment of the experience hall, it has improved the awareness and loyalty of social consumer groups to the Katazai brand, and also improved the desire to buy products, with nearly 400 experience halls
in the country.
In the 2022 semi-annual report, Katazai mentioned that it is necessary to build a "Katazai Famous Medical Center", which will introduce famous Chinese medicines from inside and outside the province to create a collection platform for famous Chinese medicines, a highland for traditional Chinese medicine health services and an industrial agglomeration area to meet the diversified and multi-level health service needs
of the people.
In recent years, many long-established Chinese medicine halls have adopted the "famous doctor + famous drug" model to operate, with remarkable results, the limelight is no different, how effective the company's measures are, we will continue to pay attention
to.
With 14 exclusive proprietary Chinese medicines in hand, 5 major products lead the market! 6 new Class 1 drugs are poised
With 14 exclusive proprietary Chinese medicines in hand, 5 major products lead the market! 6 new Class 1 drugs are poised Starting with proprietary Chinese medicine, the company has a first-class protected variety of traditional Chinese medicine and a number of exclusive proprietary Chinese medicines, and in recent years, the company has actively promoted industrial diversification and product diversification transformation
by using a variety of means.
by using a variety of means.
In 2020, the company successfully acquired 51% of the equity of Longhui Pharmaceutical, and successfully collected hundreds of drug approvals
.
At present, Katazai has 73 proprietary Chinese medicine products (92 approvals), distributed in 24 sub-categories, thanks to the acquisition of Longhui Pharmaceutical, the number of chemical drug products of the company has increased to 66 (the number of approvals is 66), distributed in 26 sub-categories
.
Pharmaceuticals.
At present, Katazai has 73 proprietary Chinese medicine products (92 approvals), distributed in 24 sub-categories, thanks to the acquisition of Longhui Pharmaceutical, the number of chemical drug products of the company has increased to 66 (the number of approvals is 66), distributed in 26 sub-categories
.
Table 1: Exclusive proprietary Chinese medicine under Tablets
Source: Minnet MID Drug Index Comprehensive Database
Longhui Pharmaceutical's exclusive product, Ginseng Turtle Kidney Supplement Oral Liquid, has the effect of tonifying the kidney and spleen, generating lean pulp, and has a certain improvement effect on children with mental retardation, and in 2021, the terminal pediatric other drug market in China's online pharmacies is TOP12 products
.
Earlier in the pediatric chinese medicine market, there were only two major products of pediatric cough syrup and refined monkey jujube powder, and the addition of ginseng turtle kidney oral liquid is expected to enhance the company's competitive advantage
in the pediatric chinese medicine market.
.
Earlier in the pediatric chinese medicine market, there were only two major products of pediatric cough syrup and refined monkey jujube powder, and the addition of ginseng turtle kidney oral liquid is expected to enhance the company's competitive advantage
in the pediatric chinese medicine market.
Tablets (lozenges), tablets capsules, inchoping liver capsules are the best-selling liver disease drugs, in 2021 in China's urban physical pharmacies terminal liver disease drug market, the three major products ranked top 1, TOP3, TOP10
.
In the past two years, tablets (lozenges) and tablets capsules have become extremely popular in online pharmacies and have become TOP1 and TOP2 products
.
The absolute leading position of Katazai in the retail market for liver disease drugs cannot be shaken
.
.
In the past two years, tablets (lozenges) and tablets capsules have become extremely popular in online pharmacies and have become TOP1 and TOP2 products
.
The absolute leading position of Katazai in the retail market for liver disease drugs cannot be shaken
.
Compound tablets of Zi Zi Ointment has the effect of clearing heat, detoxification, analgesicity, for shingles, herpes simplex, impetigo, folliculitis, acne, carbuncle furuncles
.
In 2021, the product ranked top 2 products in the chinese urban physical pharmacy terminal dermatology and other drug markets, and ranked top 15
in China's online pharmacy terminals.
.
In 2021, the product ranked top 2 products in the chinese urban physical pharmacy terminal dermatology and other drug markets, and ranked top 15
in China's online pharmacy terminals.
14 exclusive products have laid a large number of rivers and mountains for Katazai, but in recent years, the impact of national policies and the risk of rising raw material prices should not be underestimated, and transformation is imperative
.
Katazai has continuously increased investment in research and development, focused on the secondary development of independent advantageous varieties, and guided by clinical value, laid out new drug research and development pipelines such as innovative drugs of traditional Chinese medicine, classic recipes, and innovative drugs of chemical drugs, and continuously enriched the reserve of new products to boost
the company's performance.
According to the semi-annual report data, the company's R & D investment in the first half of 2022 increased by 82.
18%.
.
Katazai has continuously increased investment in research and development, focused on the secondary development of independent advantageous varieties, and guided by clinical value, laid out new drug research and development pipelines such as innovative drugs of traditional Chinese medicine, classic recipes, and innovative drugs of chemical drugs, and continuously enriched the reserve of new products to boost
the company's performance.
According to the semi-annual report data, the company's R & D investment in the first half of 2022 increased by 82.
18%.
Figure 3: Tablets are undergoing clinical products
Source: Minnet China Drug Clinical Trial Publicity Library
Tablets have become a veritable variety of traditional Chinese medicine, in 2020 the new lozenges for the treatment of non-resectable primary liver cancer indications were approved clinically, is currently in the phase II clinical stage, the data show that the first case of subjects has been enrolled in January this year
.
In 2021, the three major terminal 6 major markets (the statistical scope is detailed at the end of this article) The market size of the chinese patent medicine oncology disease is more than 20 billion yuan, the retail market (urban physical pharmacies + online pharmacies) maintains a positive growth trend, if the new indications are successfully approved, with the company's channel layout and brand effect in the retail market, Katazai is expected to meet another wave of volume
.
.
In 2021, the three major terminal 6 major markets (the statistical scope is detailed at the end of this article) The market size of the chinese patent medicine oncology disease is more than 20 billion yuan, the retail market (urban physical pharmacies + online pharmacies) maintains a positive growth trend, if the new indications are successfully approved, with the company's channel layout and brand effect in the retail market, Katazai is expected to meet another wave of volume
.
Chinese medicine 5 new drugs strychnine total alkali vesicle gel is intended to be used for knee osteoarthritis cold resistance choroid evidence caused by pain swelling and other symptoms, tablets and Yingkerui reached a consultation in 2016, the company provided research costs of 12 million yuan, agreed that both parties to jointly carry out clinical research of the new drug, approved clinical in 2018, is currently in the phase I clinical stage
.
.
The company's new Chinese medicine class 1 drugs also include PZH1201 for the treatment of irritable bowel syndrome, PZH1203 for the treatment of osteoarthritis, and PZH1204
for the treatment of generalized anxiety disorder.
for the treatment of generalized anxiety disorder.
In terms of new drugs of chemical drugs Class 1, PZH2111 tablets for the treatment of advanced solid tumors/hepatic cholangiobladic cell tumors were approved for clinical trials in 2020 and are currently undergoing Phase I/II clinical trials, and the data show that the first subject has been enrolled
in January this year.
Anti-tumor class 1 new drugs are currently a hot area for domestic pharmaceutical companies to develop, and the product is expected to become the first new chemical drug class 1 drug listed in Tablets
.
in January this year.
Anti-tumor class 1 new drugs are currently a hot area for domestic pharmaceutical companies to develop, and the product is expected to become the first new chemical drug class 1 drug listed in Tablets
.
In 2020, the company also won the clinical approval of PZH2108 tablets for cancerous pain; In 2021, the clinical approval of PZH2107 (LDS tablets, collaborative project) for the treatment of fibromyalgia will be obtained
.
The company is progressing smoothly in the research and development of new products, and the road of transformation of Katazai is becoming more and more stable
.
.
The company is progressing smoothly in the research and development of new products, and the road of transformation of Katazai is becoming more and more stable
.
There is only 1 Chinese medicine stock with a market value of 100 billion! Focus on retail, strengthen innovation.
.
.
Chinese medicine is still promising
Medicine.
.
Chinese medicine is still promising
As of the noon close on August 25, the threshold of the market value of the TOP10 A-share Chinese medicine enterprises was more than 20 billion yuan, but only one of them could stick to the market value of 100 billion yuan, and the old rival Yunnan Baiyao fell to 95.
55 billion yuan, and the gap between the two was getting bigger and bigger
.
At present, 6 of the TOP10 companies have announced the results of the first half of this year, and Katazai, Baiyunshan, China Resources Sanjiu, Dong'e Ejiao, and Jichuan Pharmaceutical have achieved a double harvest
of revenue and net profit.
55 billion yuan, and the gap between the two was getting bigger and bigger
.
At present, 6 of the TOP10 companies have announced the results of the first half of this year, and Katazai, Baiyunshan, China Resources Sanjiu, Dong'e Ejiao, and Jichuan Pharmaceutical have achieved a double harvest
of revenue and net profit.
Table 2: A stock market value TOP10 Chinese medicine enterprises
Note: Statistics as of 8:24 on August 12
The increase in revenue of Katazai is mainly due to the strengthening of market planning and expansion of sales channels, and the increase in sales revenue of the Company and its holding subsidiary Xiamen Katazai Hongren Pharmaceutical (consolidated); The increase in net profit was mainly due to increased
sales of the core product, the Katazai series.
The company's new strategic achievements of "multi-core drive, two-way development" are obvious, coupled with increased investment in innovation, which is expected to create a new growth point for the
company.
sales of the core product, the Katazai series.
The company's new strategic achievements of "multi-core drive, two-way development" are obvious, coupled with increased investment in innovation, which is expected to create a new growth point for the
company.
Baiyun Mountain's large commercial sector accounted for more than 60%, and the revenue in the first half of the year rose slightly, with a gross profit margin of 6.
97%, while the proportion of The Great Southern Medicine and the Great Health Sector was in the range of 10%-20%, and the gross profit margin reached more than
45%.
Affected by the epidemic, collection, medical insurance catalog adjustment and other factors, the company's performance is under pressure, but there is still some growth, the second half of the year will continue to do fine and large southern medicine, stronger and better health, deeper and more live business, bigger and more refined medical treatment, and increase investment and cohesion innovation
.
97%, while the proportion of The Great Southern Medicine and the Great Health Sector was in the range of 10%-20%, and the gross profit margin reached more than
45%.
Affected by the epidemic, collection, medical insurance catalog adjustment and other factors, the company's performance is under pressure, but there is still some growth, the second half of the year will continue to do fine and large southern medicine, stronger and better health, deeper and more live business, bigger and more refined medical treatment, and increase investment and cohesion innovation
.
In recent years, CR 39 has continuously adjusted the proportion of business segments, and the proportion of CHC's health consumer goods business increased to 65.
89% in the first half of 2022, while the proportion of prescription drugs fell to 29.
73%.
The company said that the overall operating performance in the first half of the year was mainly driven by the growth of CHC business, especially the rapid growth of professional brands, big health and other businesses; However, the growth rate of the formula granule business affected by the national standard switching and the provincial standard promotion speed has declined, the sales of the Traditional Chinese medicine injection business affected by the epidemic and the collection policy have declined year-on-year, and the growth rate of the prescription drug business has been affected
.
89% in the first half of 2022, while the proportion of prescription drugs fell to 29.
73%.
The company said that the overall operating performance in the first half of the year was mainly driven by the growth of CHC business, especially the rapid growth of professional brands, big health and other businesses; However, the growth rate of the formula granule business affected by the national standard switching and the provincial standard promotion speed has declined, the sales of the Traditional Chinese medicine injection business affected by the epidemic and the collection policy have declined year-on-year, and the growth rate of the prescription drug business has been affected
.
The net profit of Dong'e Ejiao in the first half of 2022 increased by 106%, the painful period of "destocking" has passed, and the performance recovery period has arrived
.
The proportion of ejiao and series products rose to 87.
30%, the proportion of other drugs and health care products increased to 7.
55%, the gross profit margin of the two major business segments remained above 60%, and the company is gradually reducing the proportion
of donkey breeding and sales with lower gross profit margin.
Health supplements Health supplements.
The proportion of ejiao and series products rose to 87.
30%, the proportion of other drugs and health care products increased to 7.
55%, the gross profit margin of the two major business segments remained above 60%, and the company is gradually reducing the proportion
of donkey breeding and sales with lower gross profit margin.
Jichuan Pharmaceutical's pediatric exclusive products, pediatric fever clearing granules and second-line protein iron succinate oral solution, gastric digestion oral liquid and Huanglong cough granules, contributed major increments
.
In addition to existing products, the company continues to increase the research and development and introduction of new products, actively carry out the secondary development of existing key varieties, and continuously enrich reserve products
.
.
In addition to existing products, the company continues to increase the research and development and introduction of new products, actively carry out the secondary development of existing key varieties, and continuously enrich reserve products
.
Judging from the performance of various enterprises in the first half of the year, the retail market (the growth rate of online pharmacies is amazing), and the focus on patient consumption have achieved good results, and the partial consumption of traditional Chinese medicine can become a policy haven
.
The main theme of innovation remains unchanged, independent research and development, cooperative research and development, the introduction of products and other multi-mode joint promotion, enterprises according to their own situation to choose is still promising
.
At present, the capital market is very concerned about Chinese medicine innovation, brand Chinese medicine, exclusive products, Chinese medicine formula granules, new crown prevention and treatment related Chinese medicine targets, and these areas can also become new growth points for
the company's performance.
Enterprise enterprise.
The main theme of innovation remains unchanged, independent research and development, cooperative research and development, the introduction of products and other multi-mode joint promotion, enterprises according to their own situation to choose is still promising
.
At present, the capital market is very concerned about Chinese medicine innovation, brand Chinese medicine, exclusive products, Chinese medicine formula granules, new crown prevention and treatment related Chinese medicine targets, and these areas can also become new growth points for
the company's performance.
Data source: the company's semi-annual report, intranet database note: intranet "China's three major terminals and 6 major market competition pattern", the statistical scope is: urban public hospitals and county-level public hospitals, urban community centers and township health centers, urban physical pharmacies and online pharmacies, excluding private hospitals, private clinics, village clinics, excluding county and rural pharmacies; The above sales are calculated
based on the average retail price of the product at the terminal.
Statistics as of August 25, if there are any errors or omissions, welcome to correct
.
based on the average retail price of the product at the terminal.
Statistics as of August 25, if there are any errors or omissions, welcome to correct
.
